In this paper, we historically examine the market for Factor VIII concentrate, a collection of blood products used in the treatment of hemophilia A. With the introduction of HIV-1 into the U.S. blood supply, a majority of American hemophiliacs became infected with the virus.
In response to contamination, the pharmaceutical manufacturers producing Factor VIII concentrate developed highly purified products which were introduced in the late 1980s at four to five times the price of the older, intermediate purity products.
These new products are highly valuable in protecting the 30% of hemophiliacs who are HIV-1 seronegative ; however, for those individuals previously infected by the virus, the extra benefit of the more costly products was questionable at the time they were first introduced.
Mots-clés Pascal : Facteur antihémophilique A, Commercialisation, Industrie pharmaceutique, Hémophilie, Facteur coagulation, Constituant sang, Transfusion, Contrôle pureté, Politique commerciale, Prix, Etats Unis, Aspect économique, Amérique du Nord, Amérique, Hémopathie, Coagulopathie, Maladie héréditaire
Mots-clés Pascal anglais : Factor VIII, Marketing, Pharmaceutical industry, Hemophilia, Coagulation factor, Blood product, Transfusion, Purity control, Marketing policy, Price, United States, Economic aspect, North America, America, Hemopathy, Coagulopathy, Genetic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0010277
Code Inist : 002B30A08. Création : 09/06/1995.